Emcure Pharmaceuticals Ltd.

1,891

16.5 (0.9%)stock indicator image for upward trend

As on August 19, 2026
SectorHealthcare
IndustryPharmaceuticals & Biotechnology
Basic IndustryPharmaceuticals
Market Cap36,008 Cr
P/E Ratio52.59
Dividend Yield0.02 %
Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

This image for unlock stock of the monthUnlock Stock of the Month

T&C*

Company Information


Market Insights
Open1,875
High1,908.9
NSE SymbolEMCURE
Close1,891
Low1,866.3
BSE Symbol544210
Previous Years High/Low
1 Year High2,048
3 Year High2,048
5 Year High2,048
1 Year Low1,260
3 Year Low889
5 Year Low889

Technicals


IndicatorsValueSignal
5-DMA1,916.26Bearish
10-DMA1,949.99Bearish
20-DMA1,937.45Bearish
50-DMA1,858.02Bullish
100-DMA1,759.58Bullish
200-DMA1,601.66Bullish

Historical Performance


1 Year
28.6%
3 Years
N/A
5 Years
N/A
10 Years
N/A

Shareholding Pattern


%

Values Analysis


Loading chart...

Profit & Loss

Below figures are in Rs. Crores


ParticularsMar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Net Sales78,96066,58359,85858,55460,564
Total Expenditure64,27154,28548,04645,25548,244
Other Income728570459635354
Operating Profit15,41612,86712,27113,93412,674
Interest1,7582,3712,1361,7601,981
Depreciation3,8413,1242,6012,4493,233
Profit Before Tax9,7137,2727,4729,7256,573
Consolidated Net Profit6,8134,9825,3206,6223,921
Adjusted EPS3628293722
Compounded Sales Growth
10 Years:15.9
5 Years:9.4
3 Years:6.2
TTM:3.5
Compounded Profit Growth
10 Years:21.6
5 Years:52.1
3 Years:0.6
TTM:6.5
Stock Price CAGR
10 Years:N/A
5 Years:N/A
3 Years:N/A
TTM:25.7
Return on Equity
10 Years:30.9
5 Years:21.7
3 Years:29.4
last year:36

Quarterly Results

Below figures are in Rs. Crores


ParticularsSep-2024Dec-2024Mar-2025Jul-2025Sep-2025
Sales1,70,7541,35,9361,28,5521,22,1891,05,161
Expenses63,04256,55752,45745,45934,856
Operating Profit1,07,71279,37976,09676,73070,304
OPM %63%58%59%63%67%
Other Income33,91231,75927,33324,87918,947
Interest77,78058,58459,24862,13753,713
Depreciation2,3451,6811,3851,2771,221
Profit Before Tax61,49850,87342,79638,19534,318
Tax %25%25%26%29%35%
Net Profit46,14938,15131,85727,29622,446
EPS in Rs8369585042

Balance Sheet

Below figures are in Rs. Crores


ParticularsMar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Share Capital1,8951,8121,8091,8091,809
Total Reserves42,44827,56623,05417,90820,804
Long-Term Borrowings---------------
Total Non-Current Liabilities8,11913,7719,0468,6848,829
Other Current Liabilities5,4838,5487,1226,4909,719
Short Term Borrowings4,7369,47211,32010,84612,527
Total Liabilities81,21777,09465,73459,47466,591
Capital Work in Progress1,2411,3234,0353,0982,216
Long Term Loans & Advances1,6071,4361,1431,1172,193
Currents Investments7602,997---------
Short Term Loans and Advances2,9532,3912,6752,6651,699
Total Current Assets45,55942,54538,35934,24137,174
Total Assets81,21777,09465,73459,47466,591
Adjusted Book Value234162137109125
0%
Positive
(80 to 100)
Neutral
(60 to 79)
Negative
(0 to 59)
  • The stock has a high PE of 52.59, indicating expensive valuation or elevated growth expectations.
  • Over the last three years, the stock delivered a strong 3-year price CAGR of 18.0%, indicating sustained price appreciation.
  • The stock carries a low beta of 0.5, suggesting lower volatility than the broader market.
  • In the last financial year, the company reported an EBITDA of ₹15416 million, reflecting positive operating performance.
  • In the previous financial year, the company generated revenue of ₹78960 million, indicating a large and established business.

Investment Calculator


Investment Amount: ₹ 1000000
Current Value: ₹ 1256896
No. of Shares: 665 (Approx)
Performance:25.7%
256896
NIFTY Performance: -3.9%
1 day Top Gainers
SymbolChange%
GLAXO3032.4(5%)
KAYNES3823.3(5%)
TRIVENI289.23(5%)
CYIENT894.5(4%)
RRKABEL2898.8(4%)
1 Day Top Losers
SymbolChange%
NETWEB5065(-5%)
CESC159.66(-5%)
DBREALTY101.79(-4%)
POWERINDIA33800(-4%)
HEG708.05(-4%)
BATAINDIA721.3(-4%)
3MINDIA33505(-4%)
FIRSTCRY196.5(-4%)

Top Performing Stocks from the same sector


Morepen Laboratories Ltd.

50.1%

88.42

1 Month Performance

Valiant Laboratories Ltd.

45%

91.96

1 Month Performance

Ind-Swift Laboratories Ltd.

39.1%

322.06

1 Month Performance

Sudeep Pharma Ltd.

34%

1156.4

1 Month Performance

Shilpa Medicare Ltd.

30.2%

807.75

1 Month Performance

Neuland Laboratories Ltd.

26.3%

23290

1 Month Performance

Rubicon Research Ltd.

25%

1798.8

1 Month Performance

Glaxosmithkline Pharmaceuticals Ltd.

23.5%

3032.4

1 Month Performance

Get Your Portfolio Reviewed

Stock of the Month
Stock of the Month

Latest News

Stay Updated with Our Market Newsletters

Article Image: 8 Fundamental Indicators for Stocks in 2026

January 13, 2025 | 7 min read

8 Fundamental Indicators for Stocks in 2026

Article Image: How to Research Stocks Like a Pro: Tools and Resources

October 31, 2024 | 4 min read

How to Research Stocks Like a Pro: Tools and Resources

Article Image: 8 Common Investment Jargons You Should Know

January 1, 2021 | 2 min read

8 Common Investment Jargons You Should Know

Article Image: Stock Market for Beginners: 10 Tips to Keep in Mind

November 25, 2024 | 8 min read

Stock Market for Beginners: 10 Tips to Keep in Mind

Article Image: How to Choose the Right Stocks: The Ultimate Guide

November 15, 2024 | 4 min read

How to Choose the Right Stocks: The Ultimate Guide

Article Image: The Role of Stock Market Advisory in Maximizing Returns

December 19, 2024 | 3 min read

The Role of Stock Market Advisory in Maximizing Returns